AQSZF is a Canadian specialty pharma that in-licenses products too small for larger concerns.
Along the way, a glaucoma drug in-licensed from a British company captured 8% of target market. The British company, Medcom, must be pleased with these results because they have expanded their relationship with AQSZF:
AQSZF will begin marketing Medcom products in the U.S.
AQSZF will begin marketing Medcom's line of Dry Eye treatments, known as Evolve.
As a result, operational breakeven is achievable Q4/20.
The main problem is AQSZF will run out of cash before EOY.
CEO continues to buy shares of his company.
A cap-raise is likely after a PR.
Maybe, AQSZF will be a tax loss buy after dilution.
